Borna disease virus and schizophrenia

Area of Science:

• Neurovirology
• Psychiatric Research
• Immunoserology

Background:

• Borna disease virus (BDV) is a suspected neurotropic virus with potential links to psychiatric disorders.
• Previous serological assays for BDV antibodies have limitations in sensitivity and specificity.

Purpose of the Study:

• To develop and validate a superior serological assay for detecting anti-BDV antibodies.
• To investigate the prevalence of anti-BDV antibodies in psychiatric patients with schizophrenia.
• To explore potential neuroanatomical correlates of BDV seropositivity in schizophrenia.

Main Methods:

• Development of a Western blot assay for detecting antibodies against three specific BDV proteins.
• Comparison with traditional indirect immunofluorescence assays (IFA).
• Pilot study involving psychiatric patients (schizophrenia) and healthy controls, including MRI assessments.

Main Results:

• The Western blot assay demonstrated higher efficacy than IFA for BDV serology.
• 14.4% of schizophrenia patients (13/90) showed antibodies to multiple BDV proteins, versus 0% in controls.
• The 14.5 kDa BDV protein was the most predictive marker for seropositivity.
• MRI revealed differences in putamen volume between BDV-positive and BDV-negative patients.

Conclusions:

• The Western blot assay is the preferred method for BDV serological studies.
• Detecting antibodies to multiple BDV proteins is a reliable criterion for seropositivity.
• There is tentative evidence suggesting a higher prevalence of anti-BDV antibodies in schizophrenia.
• Neuroanatomical differences may distinguish BDV-seropositive from BDV-seronegative schizophrenic patients.